Molecular pathology.
Personalized.

Solid tumor

Sarcoma

Genomic sequencing assays and analysis software

Because the global fight against cancer requires the best personalized molecular detection tools to get the right answer the first time

Sample-to-certainty targeted sequencing

NGS implementation goes far beyond sequencing. With trusted assay development capabilities, best in class molecular detection technology and purpose-built genomics analysis platform, we take you from a question to an answer you can be confident in.
Simply solving the most complex genomic problems

Archer library preparation assays are simple and work from low-input FFPE samples to provide
- Novel gene fusion detection
- Sensitive variant detection
- Robust CNV and expression information
Purpose-built analysis and integrated genomics platform
- Powerful analysis for unprecedented data quality
- Simple, intuitive user experience
- Workflow management and systems integration
- Flexible and secure local or cloud-based deployment
Scalable and flexible NGS implementation

Any of Archer’s custom or off-the-shelf assays are able to have new genes added to them without impacting assay performance. Adoption of Archer assays enables future growth based on new discoveries.
Companion diagnostic development

With the best detection technology, a global reach and ISO13485 design control, Archer is the preferred NGS CDx partner.

From sample-to-certainty

Assay Designer

Build a panel from scratch or supplement an existing assay

PreSeq^® QC

Pre-screen FFPE samples to determine DNA or RNA quality prior to library preparation

Archer^® assays

Generate libraries with Anchored Multiplex PCR (AMP™) enrichment chemistry

Sequencing

Efficiently sequence disease-targeted libraries created using Archer assays

Archer Analysis

Confidently detect fusions, CNVs, ITDs and other variants

Featured Videos

Detecting FLT3 ITDs with Archer blood cancer assays

Archer Immunoverse TCR and BCR sequencing kits

Archer in the News

Mar

2019

ArcherDX Announces Expansion of Executive Leadership Team as Company Continues to Experience Rapid Growth
ArcherDX Announces Expansion of Executive Leadership Team as Company Continues to Experience Rapid Growth

Feb

2019

Press release: ArcherDX Announces Broad-Based Strategic Collaboration with Genosity
ArcherDX, Inc. today announced that it has entered into a broad strategic collaboration with Genosity Inc., a biotechnology company that provides expertise, software and technical solutions to unlock the power of precision medicine by advancing genomics and facilitating collaborative research.

Jan

2019

Press release: ArcherDX Acquires Baby Genes, a Genetics-Based Personalized Medicine Company
ArcherDX is pleased to announce the acquisition of Baby Genes, Inc, a privately held CLIA-certified, CAP-accredited laboratory focused on empowering individuals to take charge of their health through genetic insights.

Jan

2019

Press release: ArcherDX’s Companion Diagnostic Assay for both Liquid Biopsy and Tissue Specimens Granted Breakthrough Device Designation by U.S. Food and Drug Administration
ArcherDX announced that the U.S. Food and Drug Administration (FDA) granted a Breakthrough Device designation (formerly Expedited Access Pathway program) for ArcherDx’s companion diagnostic assay application.

Dec

2018

How to decipher noisy regions with per-variant sensitivity detection
Background noise isn't static, so why should your sensitivity threshold be static? Traditional limit of detection measurements are based on static thresholds which average this noise, but Archer scientists have recently developed a method to model the noise at each base position requiring only a small set of samples. This method allows for position-specific sensitivity thresholds, termed 95 MDAF, which increases confidence in variant detection in noisy regions.

More News